Skip to main content

Table 1 Patient characteristics at baseline (week 52, the start of HOPEFUL-2) in the effectiveness analysis set (n = 135)a

From: Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study

 

ADA continuation group (n = 61)

ADA discontinuation group (n = 74)

p Valueb

ADA continuation group

p Valueb

ADA discontinuation group

p Valueb

Intensive therapy (ADA + MTX) (n = 28)

Standard therapy (MTX alone) (n = 33)

Intensive therapy (ADA + MTX) (n = 37)

Standard therapy (MTX alone) (n = 37)

Female sex, n (%)

52 (85.2)

61 (82.4)

0.82

25 (89.3)

27 (81.8)

0.49

33 (89.2)

28 (75.7)

0.22

Age, years

58.3 ± 13.6

54.5 ± 12.4

0.06

59.5 ± 12.5

57.3 ± 14.5

0.58

53.4 ± 11.2

55.5 ± 13.6

0.41

Disease duration, years

1.3 ± 0.4

1.2 ± 0.3

0.35

1.3 ± 0.3

1.3 ± 0.5

0.46

1.2 ± 0.3

1.3 ± 0.3

0.20

MTX dose, mg/week

6.9 ± 1.8

7.1 ± 1.9

0.51

6.5 ± 1.4

7.3 ± 2.0

0.03c

7.0 ± 2.0

7.3 ± 1.8

0.19

Steroid use, n (%)

17 (27.9)

17 (23.0)

0.55

7 (25.0)

10 (30.3)

0.78

5 (13.5)

12 (32.4)

0.10

TJC28 score

0.7 ± 1.1

1.0 ± 2.0

0.93

0.4 ± 0.7

0.9 ± 1.3

0.08

1.3 ± 2.4

0.8 ± 1.4

0.39

SJC28 score

1.0 ± 1.7

0.4 ± 0.9

0.006d

1.1 ± 1.6

1.0 ± 1.9

0.24

0.5 ± 1.0

0.3 ± 0.8

0.57

CRP, mg/dl

0.2 ± 0.3

0.1 ± 0.2

0.93

0.2 ± 0.2

0.2 ± 0.3

0.10

0.1 ± 0.1

0.1 ± 0.2

0.33

ESR, mm/h

18.8 ± 14.2

18.3 ± 13.0

0.88

18.0 ± 13.1

19.5 ± 15.3

0.90

19.4 ± 12.5

17.2 ± 13.5

0.23

EGA score (VAS, mm)

8.2 ± 8.8

7.6 ± 7.1

0.81

8.8 ± 9.5

7.7 ± 8.3

0.73

8.1 ± 7.5

7.1 ± 6.7

0.73

PGA score (VAS, mm)

9.0 ± 9.0

8.5 ± 11.0

0.27

6.8 ± 7.1

10.8 ± 10.1

0.08

7.7 ± 8.9

9.2 ± 12.9

0.46

Pain score (VAS, mm)

8.2 ± 7.5

8.5 ± 10.5

0.56

6.8 ± 7.3

9.4 ± 7.6

0.13

7.6 ± 7.6

9.4 ± 12.7

0.51

DAS28-ESR

2.5 ± 0.8

2.4 ± 0.8

0.42

2.4 ± 0.6

2.6 ± 0.8

0.28

2.5 ± 0.8

2.2 ± 0.8

0.08

DAS28-CRP

1.8 ± 0.5

1.7 ± 0.6

0.23

1.8 ± 0.5

1.9 ± 0.5

0.35

1.8 ± 0.6

1.7 ± 0.6

0.52

HAQ-DI score

0.193 ± 0.273

0.199 ± 0.303

0.68

0.125 ± 0.167

0.250 ± 0.329

0.20

0.213 ± 0.296

0.186 ± 0.313

0.57

Erosion score

6.0 ± 7.7

7.1 ± 9.7

0.08

4.3 ± 4.8

7.3 ± 9.3

0.12

6.7 ± 12.3

7.5 ± 6.1

0.09

JSN score

3.4 ± 3.6

6.7 ± 13.1

0.31

2.2 ± 1.8

4.5 ± 4.4

0.04c

5.4 ± 15.1

8.1 ± 10.8

0.01c

mTSS

9.4 ± 10.4

13.9 ± 21.9

0.09

6.5 ± 5.9

11.8 ± 12.6

0.04c

12.1 ± 27.2

15.6 ± 15.0

0.02c

MMP-3 (ng/ml)

55.2 ± 44.1

60.7 ± 48.1

0.63

52.7 ± 31.9

57.4 ± 52.6

0.80

65.5 ± 49.9

56.0 ± 46.5

0.21

RF (U/ml)

62.8 ± 90.8

42.6 ± 51.8

0.85

50.6 ± 94.1

73.1 ± 88.1

0.11

41.8 ± 35.3

43.4 ± 64.8

0.26

ACPA (U/ml)

169.3 ± 257.8

216.2 ± 654.8

0.41

116.0 ± 255.0

214.6 ± 255.1

0.02c

167.6 ± 285.4

264.8 ± 885.0

0.10

  1. Abbreviations: ACPA Anti-cyclic citrullinated peptide antibody, ADA adalimumab, CRP C-reactive protein, DAS28-CRP 28-joint Disease Activity Score based on C-reactive protein, DAS28-ESR 28-joint Disease Activity Score based on erythrocyte sedimentation rate, EGA Evaluator global assessment, ESR Erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire Disability Index, JSN Joint space narrowing, MMP-3 Matrix metalloproteinase 3, mTSS Modified total Sharp score, MTX Methotrexate, PGA Patient global assessment, RF Rheumatoid factor
  2. a Values are expressed as mean ± SD, unless otherwise indicated
  3. b Statistical significance assessed by the Wilcoxon rank sum test
  4. c p < 0.05 ADA continuation group versus ADA discontinuation group, or initial intensive therapy (ADA + MTX) group versus standard therapy (MTX alone) group
  5. d p < 0.01 ADA continuation group versus ADA discontinuation group, or initial intensive therapy (ADA + MTX) group versus standard therapy (MTX alone) group
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us